Australia approves swine flu vaccine; trials in pregnant women in US
This article was originally published in SRA
Executive Summary
Pharmaceutical companies around the world are making progress in tackling the 2009 H1N1 influenza (swine flu) virus. Australia’s Therapeutic Goods Administration is the latest regulatory authority to grant approval to an H1N1 vaccine1,2. Approval was granted using the so-called progressive assessment process, whereby the TGA analysed data on a rolling basis as they became available.
You may also be interested in...
EU Nitrosamines Oversight Group Sets Priorities
After agreeing on an EU-wide harmonized approach to deal with nitrosamine contamination in medicines, a recently formed regulatory oversight group has identified several topics requiring further scientific discussion.
EMA Reviews GSK/Vir’s COVID-19 Antibody To Support Early Use By Member States
After preliminary discussions with its pandemic task force, the European Medicines Agency has begun reviewing GSK/Vir Biotechnology’s promising COVID-19 treatment to help EU national competent authorities make evidence-based decisions on its possible early use.
Coronavirus Notebook: New EMA Review To Contextualize Blood Clot Risk From AZ Jab, EU Gets Earlier Access To More Pfizer Vaccines
Denmark has stopped using the AstraZeneca vaccine completely, while the Canadian regulator is not recommending restrictions in any specific populations. Can a new EMA review provide better context to guide the vaccine’s use in different age groups and gender?